EICHORCondition: Advanced / Metastatic Solid Tumor · Sponsor: Suzhou Abogen Biosciences Co., Ltd.
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a multicenter, open-label Phase 1 clinical study to evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics, as well as preliminary anti-tumor activity of ABO2102 as monotherapy and in combination among participants with solid tumors with KRAS mutations.
This description comes directly from the study's public registry record.
Xiao Zhang · 8619931100148 · xiao.zhang@abogenbio.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. ≥18 years of age at time of informed consent. 2. Have a genetically tested report confirmed by the investigator or complete genetic testing during the screening period, with evidence of harboring any of required KRAS mutations 3. Histopathologically and/or cytologically confirmed locally advanced or metastatic solid tumors. 4. According to RECIST v1.1, at least one measurable lesion is required. 5. No severe hematological, hepatic, renal or coagulation dysfunction; laboratory test results during the screening period must meet the respective criteria specified in the study protocol. 6. Females of childbearing potential and males who are involved in heterosexual activity must agree to practice highly effective contraception. Exclusion Criteria: 1. Any other prior malignancy active within the previous 5 years, except for skin basal cell cancer that have been cured, superficial bladder cancer, or carcinoma in situ of the breast or cervix. 2. Has known symptomatic central nervous system (CNS) metastases, or CNS metastases requiring local CNS-directed therapy . 3. Received KRAS cancer vaccine before. 4. History of severe (≥ Grade 3) hypersensitivity reactions to immunotherapy. 5. History of allogeneic organ transplantation or graft-versus-host disease (GVHD). 6. Any active infection (except for hepatitis virus infection) requires systemic treatment. 7. Absence of spleen 8. Known psychiatric disorder or drug abuse that may interfere with the trial requirements 9. Participant is pregnant or breastfeeding or expecting to conceive within the projected duration of the study. 10. Other conditions that Investigators consider inappropriate for enrollment.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai, China | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07455617